Minerva Neurosciences(NERV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NERV Minerva Neurosciences

Closed Martin Luther King, Jr. Day 01-16 16:00:00 EST

4.45

+0.12

+2.77%

盘后4.45

+0.000.00%

19:52 EST

High4.51	Low4.21	Vol34.95K
Open4.36	D1 Closing4.33	Amplitude6.93%
Mkt Cap192.57M	Tradable Cap24.19M	Total Shares43.27M
T/O153.74K	T/O Rate0.64%	Tradable Shares5.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NERV","market":"US","secType":"STK","nameCN":"Minerva Neurosciences","latestPrice":4.45,"timestamp":1768597200000,"preClose":4.33,"halted":0,"volume":34950,"hourTrading":{"tag":"盘后","latestPrice":4.45,"preClose":4.45,"latestTime":"19:52 EST","volume":110,"amount":486.08,"timestamp":1768611157226,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.027713625866050834,"floatShares":5437017,"shares":43274398,"eps":-1.853295,"marketStatus":"Closed Martin Luther King, Jr. Day","change":0.12,"latestTime":"01-16 16:00:00 EST","open":4.36,"high":4.51,"low":4.21,"amount":153735.87213,"amplitude":0.069284,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.853295,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1404187200000,"exchange":"NASDAQ","adjPreClose":4.33,"preHourTrading":{"tag":"盘前","latestPrice":4.39,"preClose":4.33,"latestTime":"09:29 EST","volume":3,"amount":13.17,"timestamp":1768573799019,"change":0.06,"changeRate":0.013857,"amplitude":0.011547},"postHourTrading":{"tag":"盘后","latestPrice":4.45,"preClose":4.45,"latestTime":"19:52 EST","volume":110,"amount":486.08,"timestamp":1768611157226,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6196413011393989,"impliedVol":4.114,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/NERV/tweets","defaultTab":"tweets","newsList":[{"id":"2593458514","title":"Minerva Neurosciences Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458514","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593458514?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:06","pubTimestamp":1766437574,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences Inc. held its 2025 Annual Meeting of Stockholders on December 22, 2025. Stockholders elected two directors to the board. An amendment to the company’s certificate of incorporation to increase the total number of authorized shares of common stock was approved. An amendment to the company’s 2013 Equity Incentive Plan to increase the number of shares authorized for issuance was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the infor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL4DHRjK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV","BK4139"],"gpt_icon":0},{"id":"2584410942","title":"Minerva Neurosciences Expands Board Amid Fundraising Effort","url":"https://stock-news.laohu8.com/highlight/detail?id=2584410942","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584410942?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:58","pubTimestamp":1763560706,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences ( ($NERV) ) has shared an update. On November 14, 2025, Minerva Neurosciences appointed Dr. Inderjit Kaul to its Board of Dir...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/minerva-neurosciences-expands-board-amid-fundraising-effort?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/minerva-neurosciences-expands-board-amid-fundraising-effort?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NERV","BK4139"],"gpt_icon":0},{"id":"2584944282","title":"BRIEF-Minerva Neurosciences Appoints Dr. Inderjit Kaul To The Company’S Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2584944282","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584944282?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:55","pubTimestamp":1763560511,"startTime":"0","endTime":"0","summary":"BRIEF-Minerva Neurosciences Appoints Dr. Inderjit Kaul To The Company’S Board Of DirectorsMinerva Neurosciences Inc NERV.O:MINERVA NEUROSCIENCES APPOINTS DR. INDERJIT KAUL TO THE COMPANY’S BOARD OF DIRECTORSSource text: ID:nGNX36Q8wZFurther company coverage: NERV.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA177GJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV","BK4139"],"gpt_icon":0},{"id":"2584417849","title":"Minerva Neurosciences Appoints Dr. Inderjit Kaul to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2584417849","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584417849?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:30","pubTimestamp":1763559012,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences Inc. has appointed Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to its board of directors. Dr. Kaul will also serve as a consultant for the future clinical development of roluperidone, a treatment candidate for negative symptoms in schizophrenia. The company plans to add more board members with experience in schizophrenia clinical trials to support the upcoming confirmatory Phase 3 trial of roluperidone.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on November 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL9X42GY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","NERV","LU2095319765.USD","BK4139","IE00BKPKM429.USD","LU0314104364.USD","BK4112","LU2210149790.SGD","BK4588","LU2210150020.SGD","NDAQ","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2584941790","title":"Minerva Neurosciences Appoints DR. Inderjit Kaul to the Company’s Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2584941790","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584941790?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:30","pubTimestamp":1763559001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA177GJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NERV","BK4139"],"gpt_icon":0},{"id":"2584660029","title":"Minerva Neurosciences Files Initial Beneficial Ownership Statement for Director Inderjit Kaul","url":"https://stock-news.laohu8.com/highlight/detail?id=2584660029","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584660029?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:47","pubTimestamp":1763502467,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Inderjit Kaul as the beneficial owner in the role of Director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL8tD4CJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NERV"],"gpt_icon":0},{"id":"2583682691","title":"Minerva Neurosciences Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682691","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682691?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:44","pubTimestamp":1763156657,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences Inc. has scheduled its 2025 Annual Meeting of Stockholders for December 22, 2025. The meeting will be conducted virtually through a live webcast. Stockholders will have the opportunity to vote on various proposals as described in the company's proxy statement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL3nrCnQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV","BK4139"],"gpt_icon":0},{"id":"2582620339","title":"Minerva Neurosciences Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582620339","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582620339?lang=en_us&edition=fundamental","pubTime":"2025-11-11 12:09","pubTimestamp":1762834167,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences ( ($NERV) ) has released its Q3 earnings. Here is a breakdown of the information Minerva Neurosciences presented to its inves...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/minerva-neurosciences-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/minerva-neurosciences-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NERV","BK4139"],"gpt_icon":0},{"id":"2582817361","title":"Minerva Neurosciences (NERV) Gets a Hold from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2582817361","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582817361?lang=en_us&edition=fundamental","pubTime":"2025-11-10 09:16","pubTimestamp":1762737395,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao maintained a Hold rating on Minerva Neurosciences yesterday and set a price target of $4.00. Tsao covers the H...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/minerva-neurosciences-nerv-gets-a-hold-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/minerva-neurosciences-nerv-gets-a-hold-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NERV"],"gpt_icon":0},{"id":"2581267062","title":"Minerva Neurosciences Is Maintained at Neutral by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2581267062","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581267062?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:07","pubTimestamp":1762430820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NERV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2025 07:07 ET (12:07 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV"],"gpt_icon":0},{"id":"2581069812","title":"Minerva price target lowered to $4 from $5 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2581069812","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581069812?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:11","pubTimestamp":1762427467,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Minerva (NERV) to $4 from $5 and keeps a Neutral rating on the shares. The firm cites equity dil...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/minerva-price-target-lowered-to-4-from-5-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/minerva-price-target-lowered-to-4-from-5-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NERV"],"gpt_icon":0},{"id":"2581722627","title":"Minerva Neurosciences reports $2.7 mln Q3 net loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722627","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722627?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:39","pubTimestamp":1762346363,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences reports $2.7 mln Q3 net lossOverviewMinerva reports Q3 net loss of $2.7 mln, contrasting with net income in Q3 2024Company's Q3 operating expenses decreased due to lower R&D and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0NC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV","BK4139"],"gpt_icon":0},{"id":"2581722595","title":"Minerva Neurosciences Q3 EPS $(0.36) Misses $(0.35) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722595","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722595?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:34","pubTimestamp":1762346043,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.35) by 2.86 percent. This is a 112.12 percent decrease over earnings of $2.97 per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48649889/minerva-neurosciences-q3-eps-0-36-misses-0-35-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERV"],"gpt_icon":0},{"id":"2581724790","title":"BRIEF-Minerva Neurosciences Q3 Net Income USD -2.744 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581724790","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581724790?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345848,"startTime":"0","endTime":"0","summary":"BRIEF-Minerva Neurosciences Q3 Net Income USD -2.744 Million\n\n\nNov 05 (Reuters) - Minerva Neurosciences Q3 EPS USD -0.36.\n\nQ3 operating expenses USD 2.844 million\nQ3 income from operations USD -2.844 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX8AE3F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NERV"],"gpt_icon":0},{"id":"2581724718","title":"Minerva Neurosciences Secures $80 Million Financing and Plans Phase 3 Roluperidone Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2581724718","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581724718?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345826,"startTime":"0","endTime":"0","summary":"Minerva Neurosciences, Inc. reported its third quarter 2025 financial results and business updates. The company announced it has secured $80 million in gross proceeds from a private placement completed on October 23, 2025, with the potential to receive up to an additional $120 million if certain warrants are exercised and clinical milestones are achieved. Minerva Neurosciences stated that, following recent financing and alignment with the FDA on a confirmatory Phase 3 clinical trial, it is advancing roluperidone for the treatment of negative symptoms of schizophrenia and preparing for a potential commercial launch in the US, if approved. For the quarter ended September 30, 2025, research and development (R&D) expenses were $0.9 million, down from $1.9 million in the same period in 2024. For the nine months ended September 30, 2025, R&D expenses totaled $3.6 million, compared to $9.9 million in the prior year period. The decrease in R&D expenses was attributed to lower costs related to ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL9wrdSR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4139","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","BK4588","LU2210150020.SGD","NERV","LU2095319765.USD","LU0314104364.USD","NDAQ","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2581972409","title":"Minerva Neurosciences Q3 Operating Expenses USD 2.844 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581972409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581972409?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX8AE3F6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NERV"],"gpt_icon":0},{"id":"2581724709","title":"Minerva Neurosciences Inc: on a Path Forward to Advancing Roluperidone for Treatment of Negative Symptoms of Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2581724709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581724709?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX8AE3F6:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NERV","BK4139"],"gpt_icon":0},{"id":"2581551722","title":"Minerva Neurosciences: R&D,Admin Costs May Rise, but We’re Well Positioned to Fund Phase 3, Nda Resubmission and Launch Prep for Roluperidone in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2581551722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581551722?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:30","pubTimestamp":1762345803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX8AE3F6:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NERV","BK4139"],"gpt_icon":0},{"id":"2577687247","title":"Minerva Shares Soar on $200 Million Financing for Schizophrenia Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2577687247","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577687247?lang=en_us&edition=fundamental","pubTime":"2025-10-21 23:43","pubTimestamp":1761061380,"startTime":"0","endTime":"0","summary":"Shares of Minerva Neurosciences surged more than fourfold after the company said it has secured up to $200 million in financing to advance an investigational schizophrenia treatment through a phase 3 trial.The stock touched a high of $12.46, brushing a penny below its two-year high, in early trading, after closing Monday at $2.66. Shares had pulled back to $9.90 two hours into the morning session.The biopharmaceutical company said before the opening bell that it has entered into an agreement with institutional investors that will provide up to $200 million in gross proceeds through a private placement.The financing includes an initial upfront funding of $80 million in exchange for preferred stock, up to an additional $80 million from the exercise of Tranche A warrants and up to an additional $40 million from the exercise of Tranche B warrants.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Minerva Shares Soar on $200 Million Financing for Schizophrenia Drug Trial","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NERV"],"gpt_icon":0},{"id":"2577875016","title":"Shares of Minerva Neurosciences More Than Double After Co Secures up to $200 Million in Private Placement, Last up 163.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577875016","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577875016?lang=en_us&edition=fundamental","pubTime":"2025-10-21 21:37","pubTimestamp":1761053858,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nFWN3W225X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NERV","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.minervaneurosciences.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.1711},{"period":"3month","weight":0.7871},{"period":"6month","weight":1.2362},{"period":"1year","weight":1.0698},{"period":"ytd","weight":0.107}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.090129},{"month":2,"riseRate":0.181818,"avgChangeRate":-0.124863},{"month":3,"riseRate":0.363636,"avgChangeRate":0.000941},{"month":4,"riseRate":0.454545,"avgChangeRate":0.050114},{"month":5,"riseRate":0.545455,"avgChangeRate":0.1467},{"month":6,"riseRate":0.636364,"avgChangeRate":0.069702},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.035509},{"month":8,"riseRate":0.5,"avgChangeRate":0.304921},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.003875},{"month":10,"riseRate":0.25,"avgChangeRate":-0.122814},{"month":11,"riseRate":0.5,"avgChangeRate":0.078313},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.079275}],"exchange":"NASDAQ","name":"Minerva Neurosciences","nameEN":"Minerva Neurosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Minerva Neurosciences(NERV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Minerva Neurosciences(NERV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Minerva Neurosciences,NERV,Minerva Neurosciences股票,Minerva Neurosciences股票老虎,Minerva Neurosciences股票老虎国际,Minerva Neurosciences行情,Minerva Neurosciences股票行情,Minerva Neurosciences股价,Minerva Neurosciences股市,Minerva Neurosciences股票价格,Minerva Neurosciences股票交易,Minerva Neurosciences股票购买,Minerva Neurosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Minerva Neurosciences(NERV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Minerva Neurosciences(NERV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction